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Abstract
Chronic technology and business process disparities
between High Income, Low Middle Income and Low
Income (HIC, LMIC, LIC) research collaborators directly
prevent the growth of sustainable Global Health innova‐
tion for infectious and rare diseases. There is a need for an
Open Source-Open Science Architecture Framework to
bridge this divide. We are proposing such a framework for
consideration by the Global Health community, by utiliz‐
ing a hybrid approach of integrating agnostic Open Source
technology and healthcare interoperability standards and
Total Quality Management principles. We will validate this
architecture framework through our programme called
Project Orchid. Project Orchid is a conceptual Clinical
Intelligence Exchange and Virtual Innovation platform
utilizing this approach to support clinical innovation
efforts for multi-national collaboration that can be locally
sustainable for LIC and LMIC research cohorts. The goal is
to enable LIC and LMIC research organizations to acceler‐
ate their clinical trial process maturity in the field of drug
discovery, population health innovation initiatives and
public domain knowledge networks. When sponsored, this
concept will be tested by 12 confirmed clinical research and
public health organizations in six countries. The potential
impact of this platform is reduced drug discovery and
public health innovation lag time and improved clinical
trial interventions, due to reliable clinical intelligence and
bio-surveillance across all phases of the clinical innovation
process.
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1. Introduction
1.1 Challenges Faced by Emerging Markets and Developing
Countries in Global Health Innovation Efforts
LMICs and LICs have been impacted by chronic disparities
in the adoption and advancement of clinical trial and
population health innovation efforts, due to conflicting
regulatory requirements for Phase I to Phase IV clinical trial
models primarily defined in the Western world [1, 2]. An
excerpt from the WHO Public Health Innovation report [3]
summarizes this current dilemma: "Scientists in developing
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countries should be involved in the development of the research
protocol from the beginning to ensure that local health needs of
developing countries are taken account of. Otherwise, the reality
will be that physicians and researchers in developing countries
who take part in conducting clinical trials are placed in the role
of data collectors for trials designed only to fit the needs of people
in the developed world. Measures and policies should be imple‐
mented to ensure that these physicians and researchers can design
and initiate clinical trials that address health problems in their
own countries, rather than fulfil research protocols designed
elsewhere."
2. Examples of Impeded Progress in Emerging Markets:
India
In the last two decades, India has become one of the most
sought-after locations within the cluster of emerging
markets for global clinical trials, due to its potential for fast
recruitment of patients. However, India’s ability to sustain
its growth within the drug discovery domain continues to
be significantly challenged by both regional and global
regulatory changes [4]. According to Dr. Arun Bhatt,
President of Clininvent Research Private Limited in
Mumbai, India, the clinical trial protocols during this
period of growth within India became more complex,
demanding and inefficient for both the research teams and
patients. Between 1999 and 2005 [4], the average number of
inclusion criteria increased threefold. The average number
of procedures grew annually by 6.5%, reaching a median
number of 35 procedures in 2005. In 2012, a typical phase
III protocol included 50 eligibility criteria, 167 procedures
and 13 endpoints [4].
3. Gaps in Global Health Innovation
The root causes of these disparities are based on a lack of
an agile technology infrastructure and robust ideation
processes that can be adapted to their clinical research
environments. Fragmented clinical trial processes and
infrastructure deficiencies have left many promising
research scientists with the inability to fully collaborate
with their HIC peers. As a result, these researchers are
unable to consistently partner on acute pandemic viral
outbreaks, preventive medicine initiatives and new vaccine
development that could save millions of lives. The Inter‐
national Council for Harmonisation (ICH) has identified
the following unresolved areas of drug discovery innova‐
tion [5, 6], shown below in Table 1:
According to ICH, if these barriers are addressed, signifi‐
cant progress in the area of drug discovery and medical
innovation can be achieved, resulting in [5, 6] a reduction
in the costs of internal failures (rejects, reworks, reprocess‐
ing and investigations). This also includes optimized
regulations to enable LMICs and LICs to meet drug
discovery submission criteria and expedite the availability
of medicines to patients. There are clear signs that the
Healthcare and Life Science industries are ready to address
these barriers, due to [7, 8] a growing demand for more
focused research on infectious, rare, poverty-based and
tropical diseases worldwide. In addition, there is a re-
invigorated global movement towards clinical trial policy
harmonization and acceptance of imported, de-identified
clinical data sets for cross-trial analysis. Collectively, these
changes in the Global Health Innovation community have
resulted in the formation of new collaboration frameworks
designed to bridge infrastructure and clinical intelligence
disparities between HICs and LICs.
4. Pharmaceutical and Medical Innovation Model
Approaches
In response to the change in the industry for expanded
innovation worldwide, the International Federation of
Pharmaceutical Manufacturers and Associations (IFPMA)
has developed an innovation framework called the Phar‐
maceutical Innovation Platform (PIP). The focus of PIP is
to provide a framework for a sustainable clinical innova‐
tion model, supported by collaborative partnerships, to
achieve new heights in drug discoveries and healthcare
solutions [9]. An excerpt from its PIP framework empha‐
sizes this point [9]:
“Healthcare, science and medicine challenges are global – all
parties need to collaborate to meet these challenges effectively.
Innovation is the vital element in this effort: when the public
sector, industry, and civil society pull together to promote
innovation, public health improves and lives are saved.”
The IFPMA continues to state that PIP is not only achieva‐
ble for industrialized countries, but for developing coun‐
tries as well. “Partnerships among established R&D companies,
local R&D companies, international organizations, and local
governments can be effective ways to harness the expertise of the
various partners to find new treatments and cures for diseases
which primarily affect poor countries [9]”.
Unresolved Areas of Drug Discovery within the Global Health
Innovation Community
Fragmented approaches to quality systems related to Good Clinical
Practices (GCP) internationally
Suboptimal deployment of limited resources to identify, enact or support
effective elements of a quality system and continual improvement by both
industry and regulatory agencies
Delays may occur in the availability of medicines to patients round the world
due to vast disparities in access to robust quality management systems and
mature clinical trial practices
Delays in the implementation of innovation and continual improvement of
existing products may occur due to differences in expectation across
differing regulatory bodies around the world
Inability to implement consistently across stakeholder best practices related
to Total Quality Management in other industries, which contributes to a lack
of agility and repeatability in the quality of clinical trial practices
Table 1. ICH Barriers to Global Health Innovation
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Tenets of IFPMA PIP Model Healthcare Innovation and Delivery System Attributes
Successful Healthcare Systems • Efficient medical delivery and distribution systems
• Overall healthcare culture and policies promoting innovation
• Strong patients’ groups
• Good access to pharmaceutical information
Efficient Markets • Healthcare expenditure seen as investment, not cost
• Realistic assessment of the pharmaceuticals in improving healthcare, including the real value of
incremental innovation
• Efficient and transparent pricing and reimbursement in the decision-making process
• International price variations
Effective Use of Intellectual Property • Effective enforcement of intellectual property rights
• Sufficient and respected market exclusivity periods
• Prevention of parallel trade
Adequate and Predictable Regulatory Requirements • Stable and predictive regulatory environment
• Cooperation between regulators and industry
• Swift and transparent drug regulatory approval process
• Global harmonization of regulatory requirements
• Adjustment of regulatory requirements to advances in science and technology
Table 2. IFPMA PIP Model Attributes
Organization Purpose of Innovation Model Principles/Tenets
FDA Collaboration
Phase Playbook
The Collaboration Playbook was developed to support the
Innovation Pathways programme, sponsored by the FDA,
in an attempt to simplify and streamline the way that
innovators work with the agency. This collaboration
model is used to facilitate a more interactive and fluid
product development model during the early stages of
clinical innovation between the FDA and innovators. As
stated on the FDA website, the guiding principles behind
the Collaboration Phase include creating a shared
understanding of product success including its benefits
and risks, creating solutions that facilitate forward
progress, allowing experimentation, prototyping,
learning, and striving for greater transparency.
• Principle 1: Share an In-Depth, Common Understanding of
Success
• Principle 2: Apply Best Practices in Framing Benefit and Risk
• Principle 3: Create Solutions that Facilitate Forward Progress
• Principle 4: Improvise, Experiment, Prototype, Test, and Learn
• Principle 5: Full Transparency in Decision Making
WHO Health “3D”
Innovation Cycle
The 3D Innovation Cycle represents a schema that applies
principally to developed countries and the diseases which
predominantly affect them, where effective demand and
the population’s health needs most closely coincide. For
conditions such as cancer and asthma, incremental
improvements are commonplace, and companies have a
reasonable assurance that healthcare providers and
patients will purchase their products. That provides the
basic economic and financial incentive for innovation.
Whatever the various problems encountered in the
innovation cycle, either technical or in terms of the policy
framework, it broadly works for the developed world and
sustains biomedical innovation directed at the
improvement of public health. (Excerpt from the 2006
WHO report Public Health Innovation and Intellectual
Property Rights: Report of the Commission on Intellectual
Property, Property Rights, Innovation and Public Health.)
The 3D Innovation Cycle is an iterative framework that consists of







◦ Preclinical and Clinical Development
• Market Approval and Manufacture
• Delivery
◦ Getting Products to Patients
Table 3. Summarized Collaborative Innovation Models from FDA and WHO
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The IFPMA’s PIP model is composed of healthcare delivery
characteristics that are necessary for an effective clinical
innovation environment to grow locally, nationally and
internationally [9]. Table 2 lists the attributes that the
IFPMA outlines in its PIP model [9].
The model goes into greater detail regarding the tactical
aspects of each of these areas. We saw in our research
congruent themes between IFPMA, WHO and FDA in this
regard, pertaining to scalable clinical innovation models for
LMICs and LICs to use as their strategic compass in
navigating towards locally sustainable research efforts.
Table 3 is a summary of both the FDA’s and WHO’s
adaptable innovation models.
The model ultimately enables LMIC and LIC innovators to
transition from being the primary recipients of innovation,
to originators of clinical innovation. It will also take bold
and unconventional thinking in order to overcome the
socioeconomic and infrastructure barriers that innovators
face within these regions of the world. Both WHO and the
FDA provided solid narrative guidance on implementation
approaches to their models. However, there was limited
evidence, beyond their illustrative examples, of the
measurable outcomes of the use of these models by LMICs
and LICs in our systematic review. This has inspired our
thinking as healthcare innovators, to re-architect and
integrate best practices from IFPMA, WHO, the FDA, and
the new agile Open Source technology and Open Science
frameworks, which are gaining greater acceptance as a
platform of choice for clinical intelligence communities, as
the next generation of collaborative research [10].
5. Next Generation of LMIC and LIC Virtual
Collaboration Models
The movement towards Open Source-Open Science
collaboration is evident with the new e-health platforms
that are taking shape to address these challenges. As the
Global Health community enters into a broader range of
eHealth adoption efforts, we see pioneering growth and
expansion of mHealth (mobile phone technology used for
healthcare data exchange and patient engagement) solu‐
tions that are taking a progressive approach to enabling
more effective patient engagement and peer-to-peer
clinical decision support at the point of care. This has also
led to supporting new patient engagement research models
for public health bio-surveillance and education efforts
related to infectious disease prevention and control and
medication adherence in LIC and LMIC regions of the
world. As a result, some mHealth initiatives have moved
the needle with the adoption of new patient engagement
efforts, simply due to leveraging this new technology. Yet
it is still in its infancy as a stand-alone solution that ignites
locally based clinical innovation. The impact and sustain‐
ability of clinical innovation powered by mHealth solutions
are still uncertain, due to the following factors outlined by
WHO in its 2015 guide for mHealth solutions [11], shown
in Table 4 below:
The goal of an integrated Open Source-Open Science
platform is to take mHealth one step further, by enabling
re-usable clinical intelligence that can be shared and re-
distributed in the context of clinical innovation before,
during and after care is delivered. As a result, mHealth thus
becomes an essential building block to this framework by
providing a timely data feed for the innovation process.
When mHealth is coupled with an Open Source-Open
Science virtual collaboration environment, it will enable
LMIC and LIC research scientists to engage in interactive
drug discovery and global knowledge sharing for clinical
innovation. As a result, it may reduce drug discovery lag
time, by enabling timely collaborative clinical trial data
sharing and bio-surveillance intelligence across all phases
of drug discovery.
6. Conceptual Open Source-Open Science System Design
Approach
Our conceptual Open Source-Open Science model, Project
Orchid, incorporates the above requirements, in order to
strengthen existing clinical trial partnerships and support
new collaborative efforts that have disparate geographic,
cultural and regulatory drivers. We have designed an
integrated operational governance and clinical innovation
engagement platform that can be adapted to the needs of
each stakeholder organization. The intent of our model is
to illustrate, through a multi-national TB clinical trial
cohort, the potential outcomes of using the Open Source-
Open Science framework (Table 5).
7. Open Source-Open Science Innovation Framework
Project Orchid consists of two integrated offerings: An
Innovation Engagement Framework and a technology-
enabled Collaboration Platform (Figures 1 and 2), de‐
signed to address disparate institutional and cultural
barriers that impede medical innovation, by providing
Clinical Research Organizations, government-sponsored
public health and research agencies, academia, non-
government/non-profit agencies and pharmaceutical and
medical device companies with an interactive drug
WHO Factors that Impede mHealth Adoption
• Conflicting healthcare priorities
• Unsustainable operating costs
• Inability to consistently measure clinical and cost effectiveness
• Lack of harmonized healthcare policy and governance models to support
mHealth/telehealth initiatives
• Lack of knowledge concerning the possible application of mHealth and
public health outcomes
• Lack of IT infrastructure to support mHealth and telehealth programmes
• Patient literacy, privacy and cultural issues
Table 4. Factors that Prohibit Growth of mHealth Solutions for Global
Health Innovation
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discovery environment and best practices framework, to
harmonize their clinical trial and public health programme
governance approaches to produce improved research and
care delivery outcomes.
8. Open Science Collaboration Maturity Model
Our proposed Open Science Collaboration Maturity
Model is used to identify and address current process,
resource and competency gaps and disparities in key areas
that impede medical innovation across the group of
stakeholder organizations. This exercise will enable
innovation teams to apply knowledge management,
process harmonization and re-engineering techniques and
risk mitigation strategies to bridge potential points of
failure within the collaboration effort. The model is a
process performance hierarchy, designed to address peer-
to-peer organizational disruption, due to change manage‐
Collaborative Drug Discovery Strategy & Outcomes
Goals • Establish an Open World Clinical Trial Collaboration
Metaverse environment to facilitate Toxicity and Efficacy
data sharing and Bio-surveillance across Clinical Trial
Genomic Avatars
• Host a scalable technology platform for Adaptive
Clinical trial frameworks
Challenges • Language Barriers
• Clinical practice and operational governance
differences across countries
• Lack of integrated Health Information Exchange
Networks and/or gateways outside of native Health IT/
Information Management ecosystem for cross-trial data
sharing and analysis
• Lack of harmonized Clinical Imaging Trial data
management and workflow approaches
• Clinical practice and operational differences, which
limit innovation opportunities outside of organization
Expected
Outcomes:
• Enable accelerated data harvesting and optimized bio-
surveillance of potential serious adverse events across
multiple genomic profiles that meet Phase II/Phase III
data monitoring requirements for ICH and FDA
investigational new drugs/vaccines
• An established Open Science Knowledge Network for
cross-trial data analysis within a defined research
community
Shared Systems: • Project Orchid Platform






• ICH Technical Specifications for Harmonization
• The three National and Regional Clinical Trial
Regulatory Frameworks
Table 5. Open Source-Open Science Clinical Trial Platform - Multi-National
TB Drug Discovery Strategy
ment stressors that new medical innovation partnerships
experience as an outcome of joint programme initiatives
with financial and regulatory considerations. The focus of
the model is designed for both healthcare solution devel‐
opment (i.e., Population Health initiatives for Public Health
programmes) and drug discovery efforts, across national
and multi-national engagements. Project Orchid’s Model is
based on three integrated aspects of collaboration:
• Programme and Policy Harmonization: This consists of
addressing regulatory and cross-cultural organizational
dynamics, process adoption and motivation models.
• Ideation and Strategy: This consists of addressing
medical innovation modelling and clinical trial bridging
strategies.
• Operational Engagement: This consists of facilitating,
across the cohorts, the identification of service-level key
performance indicators, knowledge management and
delivery system optimization efforts after the launch of
their medical innovation.
The structure of the model is to encourage transparency
and process agility, while leveraging the collective
strengths of all stakeholder organizations in order to
accelerate opportunities for business development, prod‐
uct innovation and service management in a more fluid
manner. This framework aligns to the ICH Quality System
concept tenets: Process Performance and Product Quality
Monitoring System Corrective Action/Preventive Action
(CA/PA); System Change Management; System Manage‐
ment Review; Knowledge Management and Quality Risk
Management [5, 6]. Each level of the maturity model
corresponds to a key set of measures and methods that a
collaborative partnership focuses on in its efforts to enable
sustainable innovation. A facilitated Strengths, Weakness‐
es, Opportunities and Threats (SWOT) analysis is done
across all core stakeholders of the partnership to determine
how to address disparities in the “as-is” and “to-be” model
for collaboration, followed by a risk mitigation and change
management governance model adopted at all levels of the
joint venture. The structure of the model is to encourage
transparency and process agility, while leveraging the
collective strengths of all stakeholder organizations in
order to accelerate opportunities for business develop‐
ment, product innovation and service management in a
more fluid manner [10-13].
It is recommended that, prior to initiating a formal collab‐
orative partnership, an organization should perform a self-
assessment to be fully aware of its SWOT findings and
perform an internal cognitive walkthrough, or “what if”
scenario with potential partnerships, in preparation for
change management stressors or business drivers that may
be encountered as part of the harmonization effort for joint
ventures [12, 13]. The table below (Table 6) itemizes each
level of the maturity model and how it is applied across all
three domains of the collaboration framework.
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9. Clinical Trial Data Quality and Regulatory Policy
Harmonization
The incremental nature of the Collaboration Maturity
Model can be applied when multi-national research teams
with LIC and LMIC partners attempt to harmonize the
following GCP frameworks and regulatory standards that
align to key bioethics and privacy guidelines related to the
Clinical Trial Data Management system used in the Life
Science industry. They include, at a minimum, the stand‐
ards listed in Table 7:
10. Open Source-Open Science Solution Architecture and
System Design
A proposed Open Source-Open Science Collaboration
solution architecture should leverage Open Source tech‐
nology frameworks for 2D and 3D data visualization and
healthcare interoperability standards, such as HL7 Fast
Healthcare Interoperability Resource (FHIR), Clinical Data
Architecture (CDA) and Digital Imaging and Communica‐
tion in Medicine (DICOM) standards, which are widely
used in electronic medical records, medical devices, picture
archiving systems and registries worldwide, to enable
system-to-system integration and data exchange across the
clinical research and care management continuum [13-20].
Open Source-Open Science platforms, like Project Orchid,
will also leverage technology components, such as Linux
and Drupal, and long-term scalable telecommunication
frameworks, such as Internet2 and Unified Communica‐
tion protocols, which optimize secured clinical data
exchange in low bandwidth regions of the world. The
proposed implementation model for Project Orchid is to
incorporate these standards (Table 8) within Project
Orchid’s capabilities as a shared Platform-as-a-Service
offering, to enable global pharmaceutical and biotechnolo‐
gy firms and government-based Life Science agencies to
bridge the clinical data exchange connectivity divide with
their LIC and LMIC pilot sites, which have very limited IT
and mHealth infrastructure resources.
11. Unified Communication and Usability Standards
The following table (Table 9) is a partial list of the protocols
and standards that will be used in the development of the
Unified Communications recommended by Texas A&M
Internet2 Technology and Evaluation Center (ITEC).
We will also use the ISO 9241-11 standard to verify the
following criteria for user interface design, recommended
by Virginia Tech’s Advanced Research and Computing,
Visionarium Lab: effectiveness, efficiency and satisfaction
Figure 1. Project Orchid Open Source-Open Science Innovation Framework
Figure 2. Project Orchid Collaboration Maturity Model
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(ISO 1998). This will take into account both the visually and
hearing impaired as well. The use of these standards will
ensure effective adoption across diverse organizational,
language and cultural attributes for our proposed multi-
national pilot programme.
12. Open Science User Profiles
In order to ensure that each member of the initiative has the
appropriate access rights to the Open Source-Open Science
Platform, the system will provide role-based capabilities to
maintain the data integrity of the system and ensure
alignment to Good Clinical Practices (GCP). Table 10 is a
limited representation of a typical user profile configura‐
tion that a Clinical Research Organization (CRO) may
collaborate with.
13. Implementation Model for an Open Source-Open
Science Initiative
In order to illustrate how an Open Source-Open Science
platform can be implemented for a viable clinical innova‐
tion effort across multi-national stakeholders, Project
Orchid has targeted two scenarios: a multi-national Phase










audit exercises per the
specifications of the regulation(s)
• Programme and Policy
Harmonization







Business Value Statements and
Public Policy Guidelines
Self-audit and programme-level
audit exercises per the
specifications of the adopted set of
organizational ethics
• Programme and Policy
Harmonization





























Vendor attestation for technical
conformance via interoperability
assessments and the use of Open
Source tools
• Programme and Policy
Harmonization
















requirements that directly impact
business and system-level
operational performance
• Operational Engagement Project Initiation and










KPIs and system-level non-
functional requirements that have
been designated as market
differentiators in overall
performance improvement for the
initiative
• Ideation and Strategy
• Operational Engagement
Project Initiation and





Inspiration The intrinsic reward of
achieving the goals of
partnership and its impact on
the recipients of the product/
service and industry as a whole
Revisiting the mission and vision
statements of each stakeholder,
highlighting the ideals they
promote and incorporating them
within the culture of the initiative
• Programme and Policy
Harmonization
• Ideation and Strategy
• Operational Engagement
Throughout the course
of the partnership as a





Table 6. Project Orchid Collaboration Maturity Model Reference Table
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III TB Clinical Trial for Drug Toxicity/Efficacy and Bio-
surveillance; and a supporting Open Science Knowledge
Network to disseminate clinical intelligence to a specific TB
research collaboration community. Our goal is to pilot this
concept with our research partners.
14. Multi-National TB Phase II/III Clinical Trial Toxicity
and Efficacy 3D Bio-surveillance
The scope of the proof of concept and pilot is to build, test
and deploy, in the field, an Open World Clinical Trial
Collaboration Metaverse ecosystem between several
central and sub-Saharan African countries, India, and the
US, to facilitate a TB Vaccine Toxicity and Efficacy cross-
trial data sharing initiative. The technology platform will
simulate a vaccine development initiative across these
locations with a shared virtual collaboration network that
has a 2D/3D Genomic Toxicity and Efficacy Avatar envi‐
ronment, to detect and monitor toxicity and efficacy
outcomes of specific formularies in Phase II/III TB clinical
trials. The Human Avatar will display growing or dimin‐
ishing contraindications that are reported via Case Report
Forms from the participating researchers, as well as other
relevant data feeds, such as laboratory information sys‐
International-Based Clinical Data Quality Standards and Guidelines US-Based Clinical Quality Data Standards and Guidelines
ICD-10
ICH (International Council for Harmonisation) Guidance Documents for Good
Clinical Practices




World Medical Association Declaration of Helsinki
• Dept. of Health and Human Services Agency for Healthcare, Research and
Quality Registry Standards and Guidelines
• Dept. of Health and Human Services FDA Code of Federal Regulations Part
II Electronic Signatures and Records
• Dept. of Health and Human Services FDA Computerized System Used in
Clinical Trials - Good Clinical Data Management Practices, version 4
• (CDISC) Clinical Data Interchange Standards Consortium, Operational Data
model (ODM)
• (CONSORT) Consolidated Standards of Reporting Trials documentation
• Dept. of Human Services Health Insurance Portability and Accountability
Act (HIPAA) Personal Health Information (PHI) regulations for covered
entities and business associates and Federal Patient’s Rights policies for Opt-
In/Opt-Out Data Sharing events
• Society for Clinical Data Management Guidelines for clinical trial quality
management systems















• Open Source Server
Solutions
• HTML 5
• NIH Common Data Element
• NIH - Agency for Healthcare
Quality and Research Patient
Registry
• HealthIT.gov Quality Data
Model






• The Open Group
Architecture Framework v 9.1
• HL7 FHIR, CDA R2
• DICOM for Radiology
• IHE Quality Profiles
• Health IT.gov S&I Framework
• ISO 9241-11
• My Blue Button
• WHO Health Technology
Assessment for Medical
Devices
• European Network for
Health Technology
Assessment – The HTA Core
Model
Table 8. Project Orchid Open Source Technology, Data Architecture and Health Interoperability Frameworks
Standard Unified Communication Protocols Description
IETF RFC 3261 – Session Initiation Protocol (SIP) • This is the basis of all current voice and video communications globally. It is used for
establishing communications channels. There are at least 40 other RFCs associated with SIP
that are used for various aspects of the call setup
IETF RFC 3428 SIMPLE Protocol • This standard supports Instant Messaging over SIP
IETF RFC 5139 Presence Information Data Format Location
Object (PIDF-LO)
• This is the industry standard format for embedding location information into a message
IETF RFC 4566 Session Description Protocol • This standard allows end users to connect via voice, video, text or other media
OASIS Common Alerting Protocol (CAP) • This is the standard that allows the transmission of emergency alert mass notifications
Table 9. Project Orchid Unified Communication Protocols
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tems, health information systems, or radiological imaging
systems, with projected toxicity or efficacy modelled by the
current drug formulary under investigation. These results
will be viewable on a toxicity and efficacy intelligence
dashboard and a three-dimensional heat map of the areas
affected on the Avatar. For example, targeted organs, such
as the kidneys or liver, can be highlighted and “virtually
scanned” for image manipulation and shared across the
clinical research community for analysis. We will also
include Open Source and DICOM viewers for 2D and 3D
radiology images and pathology samples from submitted
patient-level data sets for peer-to-peer consultations and
retrospective clinical analysis on short- and long-term
therapeutic outcomes.
The results will also be fed into a Cross-Trial Drug Toxicity
and Efficacy Registry for concurrent and systematic review
by regulatory bodies, the sponsoring IRB, and Data
Monitoring committees within the research community.
The following organizations have confirmed their interest
in participating in usability testing and piloting this Project
Orchid scenario:
• D-Tree International: An NGO that specializes in Public
Health programmes and mHealth solutions in sub-
Saharan Africa and India
• Handheld Solutions and Research Labs (HANDSREL):
HANDSREL is a company based in Bangalore, India,
which develops and provides mobile data collection
solutions and services
• ITOCA (Information Training and Outreach Centre for
Africa): ITOCA is a South Africa-based NGO training,
research and outreach centre for clinical research and
academic institutions in Africa and their partners
• Muhimbili University of Health and Allied Sciences, Dar
es Salaam, Tanzania
• Central Africa Network on TB, HIV/AIDS and Malaria:
A consortium of the University of Tubingen, Germany,
and eight clinical research institutions in the Republic of
the Congo, Gabon and Cameroon
• Programme of Health of Reproduction and Family, an
NGO from the Democratic Republic of Congo
• Virginia Tech Advanced Research Computing-Informa‐
tion Technology and Visionarium Lab
• Texas A&M Internet2 Technology Evaluation Center
• University of Maryland College of Information Studies
Below are diagrams (Figures 3 and 4) that illustrate the
Project Orchid conceptual collaboration platform.
15. Conclusion
The current solutions in the LIC and LMIC clinical innova‐
tion domain are primarily third party vendor systems,
which require unsustainable IT infrastructure and software
management support, or heavily paper-based processes
supplemented with standard IT desktop applications and
databases. There are also very limited Open Source-Open
Science, health information exchange and mHealth net‐
works that are integrated into multi-national cohorts and
these do not address the dynamic clinical trial frameworks
used in drug discovery. Collectively, these systems do not
enable the robust capabilities needed to sustain near-real
time clinical innovation or meet the regulatory standards
for compliance to GCP systems for clinical trial data
management. As a result, LICs and LMICs cannot transi‐
tion effectively from manual administrative efforts in order
to participate in multi-national clinical trials and public
health innovation, which directly impedes their ability to
mature as an organization.
As a Global Health community, we must advocate for both
agnostic and agile technology architecture frameworks that
enable technical, syntactical and semantic interoperability
and business process harmonization across LIC and LMIC
cohorts and their MIC and HIC stakeholders, for true
clinical innovation progress worldwide. Open Source and
Open Science Innovation frameworks are leading this
incremental transformation in our Life Science domain.
This movement has become our next wave of healthcare
Clinical Innovation User Profiles
Principal/Chief Investigator
CRO/Site Level Clinical Investigator
Clinical Trial Quality System Lead/Engineer
Investigational Review Board Member
Data Monitoring Members, Research Librarians and Healthcare Data Stewards
Pharma/Biotech CRO sponsors
Site Level Research Scientists and Epidemiologists
IT and Telecommunication System Administrators
Clinician and Healthcare Workers
Clinical and Public Health Regulatory Grantor Representatives
Table 10. Project Orchid Open Science User Categories
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modernization and disruption, in bridging the digital
divide within our Global Health community.
This is also driving the development of new health IT
solutions around the world. From our observation and
implementation experience, the most effective disruptive
technology solutions within the Global Health domain for
clinical innovation will need to provide scalable Open
Science-Open Source life science solutions, specifically
designed and priced to meet the data sharing challenges
that LIC and LMIC clinical research and public health
organizations face in clinical trial and medication innova‐
(Countries in illustration do not represent current partners)
Figure 3. Project Orchid Clinical Trial Innovation Platform for Infectious Disease Drug Discovery
Figure 4. Project Orchid Open Science Digital Library and Knowledge Network
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tion efforts in a global market. This entails developing re-
usable and extensible technology that can integrate with
local and international health information exchange
networks that support data liquidity between proprietary
and Open Source electronic medical record systems,
laboratory and radiology systems and mHealth platforms,
which are on a par with MICs and HICs. In addition, they
will need to provide virtual Open Science collaboration
environments, which enable access to near-real time
clinical intelligence, science breakthroughs and new drug
discovery partnerships that can accelerate the business
development capabilities of LMICs and LICs in the Life
Science industry. An example of this is the 2D/3D Open
World Metaverse and Digital Library we are developing
within our proof of concept.
The opportunity for innovation empowerment is within
reach for emerging markets and LMICs, when global
ingenuity meets Open Source-Open Science technology.
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